Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib.

Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib.
复制标题

胰腺癌的合成致命性:发现一种新的RAD51-BRCA2小分子干扰物,它能抑制同源重组并与奥拉帕利协同作用。

DOI:
10.1021/acs.jmedchem.9b01526
复制
发表时间:
2020-03-12
影响因子:
7.3
通讯作者:
Cavalli A
Cavalli A
中科院分区:
医学1区
文献类型:
--
作者:
Bagnolini G;Milano D;Manerba M;Schipani F;Ortega JA;Gioia D;Falchi F;Balboni A;Farabegoli F;De Franco F;Robertson J;Pellicciari R;Pallavicini I;Peri S;Minucci S;Girotto S;Di Stefano G;Roberti M;Cavalli A

文献摘要

参考文献

被引文献

相似文献

合成致死性是发现新型抗癌候选药物的创新框架。一个例子是在BRCA突变的肿瘤患者中使用PARP抑制剂(PARPi)。在这里,我们开发了一种基于仅使用小有机分子(被称为“完全小分子诱导的合成致死性”)触发合成致死性的可能性的新范例。我们利用这种模式来针对胰腺癌,这是肿瘤学中未被满足的主要需求之一。我们发现了一种基于二氢喹诺酮吡唑啉的分子(35d),它破坏了RAD51-BRCA2蛋白之间的相互作用,从而模仿了BRCA2突变的影响。35d抑制人胰腺腺癌细胞系同源重组。此外,它与奥拉帕尼(一种PARPi)协同作用,触发合成致死。该策略旨在扩大PARPi在brca阳性和奥拉帕尼耐药癌症中的应用,使完全小分子诱导的合成致死性成为解决未满足肿瘤需求的创新方法。
Synthetic lethality is an innovative framework for discovering novel anticancer drug candidates. One example is the use of PARP inhibitors (PARPi) in oncology patients with BRCA mutations. Here, we exploit a new paradigm based on the possibility of triggering synthetic lethality using only small organic molecules (dubbed “fully small-molecule-induced synthetic lethality”). We exploited this paradigm to target pancreatic cancer, one of the major unmet needs in oncology. We discovered a dihydroquinolone pyrazoline-based molecule (35d) that disrupts the RAD51-BRCA2 protein–protein interaction, thus mimicking the effect of BRCA2 mutation. 35d inhibits the homologous recombination in a human pancreatic adenocarcinoma cell line. In addition, it synergizes with olaparib (a PARPi) to trigger synthetic lethality. This strategy aims to widen the use of PARPi in BRCA-competent and olaparib-resistant cancers, making fully small-molecule-induced synthetic lethality an innovative approach toward unmet oncological needs.
DOI: 10.1021/jm1002974
发表时间: 2010-08-12
影响因子: 7.3
作者:
Nomme, Julian;Renodon-Corniere, Axelle;Takahashi, Masayuki
通讯作者: Takahashi, Masayuki
DOI: 10.1038/nrd3374
发表时间: 2011-05
影响因子: 120.1
作者:
Chan, Denise A.;Giaccia, Amato J.
通讯作者: Giaccia, Amato J.
DOI: 10.1111/j.1365-2443.2008.01180.x
发表时间: 2008-05-01
期刊: GENES TO CELLS
影响因子: 2.1
作者:
Nomme, Julian;Takizawa, Yoshimasa;Takahashi, Masayuki
通讯作者: Takahashi, Masayuki
DOI: 10.1016/s1097-2765(01)00175-7
发表时间: 2001-02-01
期刊: MOLECULAR CELL
影响因子: 16
作者:
Davies, AA;Masson, JY;West, SC
通讯作者: West, SC
DOI: 10.1021/jm400652r
发表时间: 2013-08-22
影响因子: 7.3
作者:
Acker TM;Khatri A;Vance KM;Slabber C;Bacsa J;Snyder JP;Traynelis SF;Liotta DC
通讯作者: Liotta DC